Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
United States Oil Fund LP
USO
5
United States Gasoline Fund Lp
UGA
US Stock MarketDetailed Quotes
Spyre Therapeutics (SYRE)
- 73.010
- +3.310+4.75%
Close Apr 17 16:00 ET
- 73.010
- 0.0000.00%
Post 20:01 ET
5.75BMarket Cap-36.87P/E (TTM)
74.600High70.210Low2.13MVolume70.320Open69.700Prev Close155.42MTurnover3.30%Turnover RatioLossP/E (Static)78.78MShares75.00052wk High10.28P/B4.70BFloat Cap12.28552wk Low--Dividend TTM64.38MShs Float318.750Historical High--Div Yield TTM6.30%Range %2.650Historical Low73.087Avg Price1Lot Size
Spyre Therapeutics (SYRE) Key Financial Indicators
SYRE Earnings per Share (EPS)
According to the latest financial report of Spyre Therapeutics, the latest earnings per share (TTM) for the company is -0.70. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
SYRE Free Cash Flow (FCF)
Interested in knowing about Spyre Therapeutics's free cash flow? The latest report shows it as -44.58M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
SYRE Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Spyre Therapeutics shows that the company's current ratio is 13.25, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
SYRE Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Spyre Therapeutics, the quick ratio is 12.89, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
SYRE Return on Equity (ROE)
Want to learn more about the financial health of Spyre Therapeutics? The latest ROE figure is -14.56%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
SYRE Return on Assets (ROA)
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Spyre Therapeutics, the total asset return on investment (ROA) is -9.75%.
Currency: USD
Quarterly
Loading...
SYRE Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Spyre Therapeutics's latest financial report to see how their gross margin is doing - currently at --.
Currency: USD
Quarterly
Loading...
SYRE Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Spyre Therapeutics, the net profit margin is -31.55K%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
Lebanon and Israel will implement a 10-day ceasefire! Iran's foreign minister, based on the Lebanon ceasefire agreement, announced the compl
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm